Phase Forward and SGS Life Science Services Sign Multi-Year, Multi-Million Dollar Agreement

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year, multi-million dollar extension of its existing partnership with leading CRO SGS. The agreement reinforces the companies’ close working relationship and offers SGS’s customers the benefits of Phase Forward’s InForm™ Global Trial Management (GTM), Clarix™ Interactive Response Technology (IRT) and Maaguzi Web-based electronic patient reported outcomes (ePRO) and late phase solutions. A Phase Forward customer since 2002, SGS is one of the largest EU data management CROs, managing nearly 100 clinical trials and processing over one million case report form (CRF) pages each year.

“Our customers are looking for an integrated eClinical solution comprising multiple systems,” said Luc Braeken, global director, Biometrics Services, SGS. “The agreement announced today will allow us to respond to customer demand for this integrated solution with innovative product sets from a market leader. This solution is designed to meet the needs of even the most demanding clinical development professional, offering more effective ways to manage clinical operations, help ensure product safety and reduce time-to-market.”

“SGS has established a reputation as a leading provider of integrated solutions from preclinical activities, to phase one through four trials,” said Mike Davies, vice president, global CRO partnerships, Phase Forward. “We look forward to building on the success of our collaboration to date with the solutions that our acquisitions of Clarix and Maaguzi add to the equation.”

About SGS Life Science Services

SGS Life Science Services, a Business unit of the SGS Group, has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I through IV trials, bio-analytical and QC testing. With more than 1,300 employees and 2,000 clinical trials performed, SGS Life Science Services serves the pharmaceutical, biotechnology and medical device industries. SGS Life Science Services Biometrics group offers comprehensive Data Management, Statistics, PK and medical writing services. Its expertise includes in-depth experience in EDC, CDISC and extensive high throughput capabilities to deliver on time.

The SGS Group is the global leader and innovator in inspection, verification, testing and certification services. Founded in 1878, SGS is recognized as the global benchmark in quality and integrity. With more than 56,000 employees, SGS operates a network of more than 1,000 offices and laboratories around the world. Additional information about SGS is available at www.sgs.com/CRO.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, demand for Phase Forward’s products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward’s customers to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, the possibility that customers’ needs or plans may change over time, the possibility that the level of demand for Phase Forward’s products and services may vary, regulatory changes and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024